Panitumumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Vectibix® |
| INN | Panitumumab |
| API type | Panitumumab is a fully human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies and antibody drug-conjugates |
| ATC code | L01FE02 |
| Target of antibody | EGFR |
| General function | Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): (1) in first-line in combination with FOLFOX or FOLFIRI, (2) in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine based chemotherapy (excluding irinotecan), and (3) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Panitumumab is a recombinant, fully human IgG2 monoclonal antibody that binds with high affinity and specificity to the human EGFR. EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR (HER1/c-ErbB-1), HER2, HER3, and HER4. EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells. Panitumumab binds to the ligand binding domain of EGFR and inhibits receptor autophosphorylation induced by all known EGFR ligands. Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin 8 and vascular endothelial growth factor production. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In vitro assays and in vivo animal studies have shown that panitumumab inhibits the growth and survival of tumour cells expressing EGFR. No anti-tumour effects of panitumumab were observed in human tumour xenografts lacking EGFR expression. The addition of panitumumab to radiation, chemotherapy or other targeted therapeutic agents, in animal studies resulted in an increase in antitumour effects compared to radiation, chemotherapy or targeted therapeutic agents alone. |
| Original license holder | |
| Marketing authorisation numbers | EU/1/07/423/001 EU/1/07/423/003 |
| Marketing authorisation holder | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands |
| Name of the manufacturer of the biological active substance | Immunex Rhode Island Corporation (ARI) 40 Technology Way West Greenwich, Rhode Island 02817 USA |
| Name and address of the manufacturer(s) responsible for batch release | Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands Amgen Technology (Ireland) Unlimited Company Pottery Road Dun Laoghaire Co Dublin Ireland Amgen NV Telecomlaan 5-7 1831 Diegem Belgium |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sodium chloride Sodium acetate trihydrate Acetic acid, glacial (for pH-adjustment) Water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
